Rezolute Stock Forecast, Price & News

-0.53 (-7.69 %)
(As of 04/12/2021 12:00 AM ET)
Today's Range
Now: $6.36
50-Day Range
MA: $10.69
52-Week Range
Now: $6.36
Volume15,913 shs
Average Volume4,788 shs
Market Capitalization$53.54 million
P/E RatioN/A
Dividend YieldN/A
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Phone650 206 4507
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$1.24 per share


Net Income$-20,330,000.00


Market Cap$53.54 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1846th out of 2,016 stocks

Pharmaceutical Preparations Industry

736th out of 771 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.53 (-7.69 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RZLTD News and Ratings via Email

Sign-up to receive the latest news and ratings for RZLTD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Rezolute (OTCMKTS:RZLTD) Frequently Asked Questions

What stocks does MarketBeat like better than Rezolute?

Wall Street analysts have given Rezolute a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rezolute wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Rezolute's key executives?

Rezolute's management team includes the following people:
  • Mr. Nevan Charles Elam, CEO & Director (Age 53, Pay $869.45k)
  • Dr. Keith A. Vendola M.B.A., M.D., MBA, Chief Financial Officer (Age 48, Pay $422.76k)
  • Dr. Sankaram Mantripragada, Chief Scientific Officer (Age 60, Pay $620.76k)
  • Mr. Michael R. Deperro, Head of Operations
  • Dr. Brian Roberts, Head of Clinical Devel.
  • Ms. Paula Opal, Head of Regulatory
  • Dr. Sharon Xueyan Wang, Head of Preclinical Devel.

Who are some of Rezolute's key competitors?

What is Rezolute's stock symbol?

Rezolute trades on the OTCMKTS under the ticker symbol "RZLTD."

How do I buy shares of Rezolute?

Shares of RZLTD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rezolute's stock price today?

One share of RZLTD stock can currently be purchased for approximately $6.36.

How much money does Rezolute make?

Rezolute has a market capitalization of $53.54 million.

How many employees does Rezolute have?

Rezolute employs 23 workers across the globe.

What is Rezolute's official website?

The official website for Rezolute is www.rezolutebio.com.

Where are Rezolute's headquarters?

Rezolute is headquartered at 201 REDWOOD SHORES PARKWAY SUITE 315, REDWOOD CITY CA, 94065.

How can I contact Rezolute?

Rezolute's mailing address is 201 REDWOOD SHORES PARKWAY SUITE 315, REDWOOD CITY CA, 94065. The company can be reached via phone at 650 206 4507 or via email at [email protected]

This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.